Liquidia Corp (LQDA)
10.46
-0.52
(-4.74%)
USD |
NASDAQ |
Nov 04, 16:00
10.50
+0.04
(+0.38%)
After-Hours: 20:00
Liquidia Research and Development Expense (Annual): 43.24M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 43.24M |
| December 31, 2022 | 19.44M |
| December 31, 2021 | 20.52M |
| December 31, 2020 | 32.22M |
| Date | Value |
|---|---|
| December 31, 2019 | 40.49M |
| December 31, 2018 | 28.70M |
| December 31, 2017 | 24.75M |
| December 31, 2016 | 23.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
19.44M
Minimum
2022
43.24M
Maximum
2023
31.18M
Average
32.22M
Median
2020
Research and Development Expense (Annual) Benchmarks
| United Therapeutics Corp | 408.00M |
| Arcturus Therapeutics Holdings Inc | 192.13M |
| Paragon 28 Inc | 30.08M |
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| AIM ImmunoTech Inc | 10.94M |